Key Takeaways
- • Hatteras Venture Partners, a Durham-based life sciences VC firm, closed more than $200 million across two new funds, including $177 million for its seventh core fund and $30 million for its inaugural Opportunity Fund, its largest raise in a quarter century according to the publisher.
- • Cape Fear BioCapital, founded in 2024 by Ed Field, Jimmy Melton, and Dave Ousterout, is targeting seed-stage North Carolina therapeutics startups, plans 8-10 investments through its Fund I, and has a planned $100 million Fund II.
- • The article reports that only 1 percent of venture capital deployed in North Carolina goes to seed or pre-seed companies, which Cape Fear cites as the core gap it aims to fill.
- • Healthcare venture funding slumped to $5 billion in the first half of 2025 versus $23 billion for all of 2024, per PitchBook, making Hatteras's raise a notable exception.
- • The article frames the developments as the start of a layered capital stack in the Research Triangle that could help retain talent and IP that have historically moved to Boston or San Diego.
Summary
The article argues that North Carolina's Research Triangle, anchored by Raleigh, Durham, and Chapel Hill, is beginning to convert its long-established scientific strength into a stronger investment base. The publisher cites North Carolina's third-place national ranking for life sciences employment, with more than 75,000 workers, alongside concentrated NIH funding, academic research output, and biomanufacturing capacity. The piece presents capital availability as the traditionally missing element.
The lead development is Hatteras Venture Partners' closing of more than $200 million across two new funds. The article reports $177 million for its seventh core fund and $30 million for its inaugural Opportunity Fund. Hatteras co-founder Clay Thorp told The Wall Street Journal, "In this environment, we feel fantastic about how we're positioned." The firm has supported more than 100 companies since its founding nearly three decades ago, including AI-driven drug discovery company Ten63 Therapeutics and oncology developer Kymera Therapeutics. Ten63 CEO Marcel Frenkel said the firm "brings much more than cash." The article notes that 15 of Hatteras's 42 tracked investments are in the Southeast, many clustered around the Research Triangle. The raise is notable against a weak market: according to PitchBook, healthcare venture funding reached only $5 billion in the first half of 2025, compared with $23 billion across all of 2024.
The article also highlights Cape Fear BioCapital, founded in 2024 by Ed Field, Jimmy Melton, and Dave Ousterout. The fund targets North Carolina therapeutics startups capable of reaching an IND in roughly three years, with support from Moore Strategic Ventures. Field said, "Our region has an abundance of life sciences innovation," but early-stage funding is needed to realize opportunities, and noted that only 1 percent of venture capital deployed in the state goes to seed or pre-seed companies. In June 2025, Cape Fear invested in Duke-affiliated companies Ten63 Therapeutics and Thoracic Therapeutics, according to the Triangle Business Journal.
The article characterizes these funds as part of a more complete capital stack that includes Pappas Capital, NovaQuest, and Alexandria Seed Capital, along with state and philanthropic actors such as the North Carolina Biotechnology Center and the Burroughs Wellcome Fund. The publisher argues this could reduce pressure on founders to relocate to Boston or San Diego, and it cites large manufacturing investments by Biogen ($2 billion expansion) and Genentech ($700 million Holly Springs site) as evidence of industry interest. The article's conclusion is that the Triangle is forming into a tier-one innovation hub, though the claims about future positioning are the publisher's assessment rather than established outcomes.
The lead development is Hatteras Venture Partners' closing of more than $200 million across two new funds. The article reports $177 million for its seventh core fund and $30 million for its inaugural Opportunity Fund. Hatteras co-founder Clay Thorp told The Wall Street Journal, "In this environment, we feel fantastic about how we're positioned." The firm has supported more than 100 companies since its founding nearly three decades ago, including AI-driven drug discovery company Ten63 Therapeutics and oncology developer Kymera Therapeutics. Ten63 CEO Marcel Frenkel said the firm "brings much more than cash." The article notes that 15 of Hatteras's 42 tracked investments are in the Southeast, many clustered around the Research Triangle. The raise is notable against a weak market: according to PitchBook, healthcare venture funding reached only $5 billion in the first half of 2025, compared with $23 billion across all of 2024.
The article also highlights Cape Fear BioCapital, founded in 2024 by Ed Field, Jimmy Melton, and Dave Ousterout. The fund targets North Carolina therapeutics startups capable of reaching an IND in roughly three years, with support from Moore Strategic Ventures. Field said, "Our region has an abundance of life sciences innovation," but early-stage funding is needed to realize opportunities, and noted that only 1 percent of venture capital deployed in the state goes to seed or pre-seed companies. In June 2025, Cape Fear invested in Duke-affiliated companies Ten63 Therapeutics and Thoracic Therapeutics, according to the Triangle Business Journal.
The article characterizes these funds as part of a more complete capital stack that includes Pappas Capital, NovaQuest, and Alexandria Seed Capital, along with state and philanthropic actors such as the North Carolina Biotechnology Center and the Burroughs Wellcome Fund. The publisher argues this could reduce pressure on founders to relocate to Boston or San Diego, and it cites large manufacturing investments by Biogen ($2 billion expansion) and Genentech ($700 million Holly Springs site) as evidence of industry interest. The article's conclusion is that the Triangle is forming into a tier-one innovation hub, though the claims about future positioning are the publisher's assessment rather than established outcomes.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.